ITOS
Closed
Iteos Therapeutics inc
10.
0 (0.00%)
Last Update: 01 Jul 2025 23:18:00
Yesterday: 9.97
Day's Range: 9.95 - 10.03
Send
sign up or login to leave a comment!
When Written:
13.45
Iteos Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery and development of innovative cancer immunotherapies. The company's proprietary platform, called "ADAPTIR," is designed to generate a new class of immunotherapies that can activate the immune system to attack tumors.
Iteos Therapeutics was founded in 2011 and is headquartered in Cambridge, Massachusetts, with additional offices in Belgium. The company went public in July 2020 and is listed on the NASDAQ stock exchange under the ticker symbol "ITOS."
The company's lead product candidate, EOS-850, is a small molecule inhibitor of the adenosine A2a receptor, which is believed to play a key role in suppressing the immune system's ability to attack tumors. EOS-850 is currently being evaluated in multiple clinical trials for the treatment of various types of cancer.
Iteos Therapeutics has collaborations with several pharmaceutical companies, including GSK, AstraZeneca, and Merck, to develop and commercialize its immunotherapy products. The company has also received funding from various sources, including venture capital firms and government grants.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Iteos Therapeutics was founded in 2011 and is headquartered in Cambridge, Massachusetts, with additional offices in Belgium. The company went public in July 2020 and is listed on the NASDAQ stock exchange under the ticker symbol "ITOS."
The company's lead product candidate, EOS-850, is a small molecule inhibitor of the adenosine A2a receptor, which is believed to play a key role in suppressing the immune system's ability to attack tumors. EOS-850 is currently being evaluated in multiple clinical trials for the treatment of various types of cancer.
Iteos Therapeutics has collaborations with several pharmaceutical companies, including GSK, AstraZeneca, and Merck, to develop and commercialize its immunotherapy products. The company has also received funding from various sources, including venture capital firms and government grants.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








